Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.

Abstract:

:We assessed the efficacy of interferon (IFN) plus ribavirin over 24 or 48 weeks for the retreatment of patients with chronic hepatitis C who had relapsed or did not respond to a previous course of IFN. One-hundred and twenty patients (69 non-responders and 51 relapsers) were randomly assigned to receive IFN-alpha2b (3 million units thrice weekly) plus ribavirin (1,000-1,200 mg per day) for 24 weeks (group A: 58 patients) or 48 weeks (group B: 62 patients). Treatment was discontinued at week 12 if the alanine aminotransferase (ALT) level remained elevated. The rate of sustained response was 15.5% in group A and 37.1% in group B (P = 0.013). Relapsers treated for 48 weeks had a sustained response rate of 66.6% compared with a sustained response rate of only 25% in those treated for 24 weeks (P = 0.004). Moreover, a sustained response was seen in 14.3% of non-responders treated for 48 weeks and in 8.8% of those treated for 24 weeks (P = 0.71). Fifty-three per cent of patients with a normal ALT level and undetectable hepatitis C virus (HCV) RNA at week 12 had a sustained response compared with 14% of those who were HCV RNA positive at week 12 (P < 0.001). Independent predictive factors of sustained response were: therapy for 48 weeks (P = 0.0026), relapse after IFN treatment (P = 0.0006), loss of HCV RNA at week 12 (P = 0.0008) and HCV genotype non-1 (P = 0.024). Hence, in patients with chronic hepatitis C who failed to respond to a previous course of IFN monotherapy, combination therapy with IFN plus ribavirin for 48 weeks seems to be more effective than IFN plus ribavirin for 24 weeks.

journal_name

J Viral Hepat

authors

Enríquez J,Gallego A,Torras X,Pérez-Olmeda T,Diago M,Soriano V,Luján MS,García-Samaniego J

doi

10.1046/j.1365-2893.2000.00243.x

subject

Has Abstract

pub_date

2000-11-01 00:00:00

pages

403-8

issue

6

eissn

1352-0504

issn

1365-2893

pii

jvh243

journal_volume

7

pub_type

临床试验,杂志文章,随机对照试验
  • Viral kinetics and early prediction of nonresponse to peg-IFN-alpha-2b plus ribavirin in HCV genotypes 1/4 according to HIV serostatus.

    abstract::To evaluate, among 70 hepatitis C virus (HCV)-monoinfected and 36 human immunodeficiency virus (HIV)-coinfected naïve patients with genotypes 1/4 receiving weight-adjusted pegylated interferon-alpha-2b/ribavirin, viral kinetics and the feasibility to predict treatment failure measuring early HCV-RNA decreases. HCV-RNA...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2005.00710.x

    authors: Moreno A,Bárcena R,García-Garzón S,Moreno L,Quereda C,Muriel A,Zamora J,Mateos ML,Pérez-Elías MJ,Antela A,Diz S,Moreno A,Moreno S

    更新日期:2006-07-01 00:00:00

  • Ongoing transmission of a single hepatitis B virus strain among men having sex with men in Amsterdam.

    abstract::For the past decade, a specific hepatitis B virus (HBV) genotype A strain has been prevalent among men having sex with men (MSM) in Amsterdam, the Netherlands. At what point in time this strain was introduced in the MSM population, and why only this specific strain continues to be transmitted, remains unclear. Between...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2009.01158.x

    authors: van Houdt R,Bruisten SM,Geskus RB,Bakker M,Wolthers KC,Prins M,Coutinho RA

    更新日期:2010-02-01 00:00:00

  • Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.

    abstract::In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly ex...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.13339

    authors: Mina M,Underwood A,Eltahla A,Wu BR,Walker MR,Bull RA,Lloyd AR

    更新日期:2020-10-01 00:00:00

  • Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.

    abstract::IL28B and inosine triphosphatase (ITPA) polymorphisms are able to predict treatment response and degree of ribavirin-related anaemia, respectively, in the treatment of chronic hepatitis C virus (HCV) infection. However, their roles in the treatment of chronic HCV genotype 6 remain undetermined. Sixty patients who were...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12047

    authors: Seto WK,Tsang OT,Liu K,Chan JM,Wong DK,Fung J,Lai CL,Yuen MF

    更新日期:2013-07-01 00:00:00

  • Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases.

    abstract::Chronic hepatitis C virus (HCV) infection leads to mixed cryoglobulinaemia (MC) and B-cell non-Hodgkin lymphoma (B-NHL). Aberrant somatic hypermutation and deregulation of the oncogene BCL-6 is associated with lymphomagenesis. Recently, HCV was shown to induce BCL-6 mutations in vitro. The BCL-6 gene (area B) was clon...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2006.00833.x

    authors: Hofmann WP,Fernandez B,Herrmann E,Welsch C,Mihm U,Kronenberger B,Feldmann G,Spengler U,Zeuzem S,Sarrazin C

    更新日期:2007-07-01 00:00:00

  • Hepatitis C virus surveillance and identification of human pegivirus 2 in a large Cameroonian cohort.

    abstract::The prevalence of chronic hepatitis C virus (HCV) and the presence of human pegivirus 2 (HPgV-2) have not been examined in Cameroon, although HCV has been associated with HPgV-2 infections previously. Herein we aimed to characterize the burden and genetic diversity of HCV and the presence of HPgV-2 in Cameroon. Retros...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12996

    authors: Rodgers MA,Holzmayer V,Vallari A,Olivo A,Forberg K,Fuhrman J,Coller KE,Awazi B,Kenmegne Sidje JB,Frankel MB,Berg MG,Mbanya D,Ndembi N,Cloherty GA

    更新日期:2019-01-01 00:00:00

  • Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C.

    abstract::Chronic hepatitis C infection leads to increased hepatocyte apoptosis. Because engulfment of apoptotic bodies (ABs) by hepatic stellate cells (HSC) is profibrogenic, we compared the effects of ABs derived from hepatitis C virus (HCV)-negative vs HCV-infected (Con1+) Huh7 hepatoblastoma cells on fibrogenic and activati...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01362.x

    authors: Gieseler RK,Marquitan G,Schlattjan M,Sowa JP,Bechmann LP,Timm J,Roggendorf M,Gerken G,Friedman SL,Canbay A

    更新日期:2011-11-01 00:00:00

  • The expression of hepatitis B virus polymerase in hepatocytes during chronic HBV infection.

    abstract::A recombinant protein corresponding to part of the amino-terminal domain of hepatitis B virus (HBV) polymerase was expressed in Escherichia coli. Antisera raised against this protein stained hepatocytes, from human liver biopsies, predominantly in the nucleus but some cytoplasmic staining was also observed. No stainin...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00083.x

    authors: McGarvey MJ,Goldin RD,Karayiannis P,Thomas HC

    更新日期:1996-03-01 00:00:00

  • A systematic analysis of the predicted human La protein targets identified a hepatitis B virus infection signature.

    abstract::The human La (hLa) protein functions in RNA metabolism and is activated by casein kinase 2 (CK2) phosphorylation. Hepatitis B virus (HBV) can exploit hLa to stabilize its RNA and promote its pathogenesis. To enhance our knowledge of host molecular pathways involved in HBV pathogenesis, a bioinformatic approach was use...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01626.x

    authors: Tang J,Zhang ZH,Liu GL

    更新日期:2013-01-01 00:00:00

  • Oxidative burst response of neutrophils primed with PreS1 antigen of hepatitis B virus in patients with chronic hepatitis B and convalescents.

    abstract::The pathogenesis of liver damage in the course of hepatitis B virus (HBV) infection depends on the host's specific and non-specific immune response to various viral antigens. The role of polymorphonuclear neutrophils (PMN) in the natural immune reaction and during secondary microbial infections is well documented. Inc...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.1996.tb00101.x

    authors: Sułowska Z,Pietruszynski R,Dworniak D,Tchórzewski H,Sidorkiewicz M

    更新日期:1996-11-01 00:00:00

  • HCV synergizes with body weight in the promotion of insulin resistance.

    abstract::Hepatitis C virus (HCV) infection appears to contribute to the development of insulin resistance (IR). Among the multiple determinants of IR, body mass index (BMI) is the most important. We investigated the contribution of HCV to BMI-associated IR using a transgenic mouse model expressing HCV core protein. Eight trans...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2010.01291.x

    authors: Delgado-Borrego A,Kamegaya Y,Jordan SH,Agrawal S,Valim C,Chung RT

    更新日期:2011-02-01 00:00:00

  • Early viral kinetics on treatment with pegylated interferon-alpha-2a in chronic hepatitis C virus genotype 1 infection.

    abstract::Even with pegylated (PEG) interferons (IFN), therapy of chronic hepatitis C (genotype 1) remains unsatisfactory. The initial viral response to IFN identifies patients infected with IFN resistant viruses not responding to standard IFN/ribavirin therapy. The impact of primary IFN unresponsiveness for PEG-IFN-alpha-2a/ri...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1046/j.1365-2893.2003.00396.x

    authors: Jessner W,Stauber R,Hackl F,Datz C,Watkins-Riedel T,Hofer H,Gangl A,Kessler H,Ferenci P

    更新日期:2003-01-01 00:00:00

  • Infection with human herpes virus type 8 in an area at high prevalence for hepatitis C virus infection in southern Italy.

    abstract::The Campania Region is a geographical area of southern Italy characterized by high incidence rates of hepatocellular carcinoma and of classic Kaposi's sarcoma. Epidemiological investigations carried out among different population groups in this region have found high prevalence rates of both hepatitis C virus (HCV) an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2004.00499.x

    authors: Montella M,Serraino D,Crispo A,Romano N,Fusco M,Goedert JJ

    更新日期:2004-05-01 00:00:00

  • Methodological issues in papers on IFN therapy: time for reappraisal.

    abstract::We conducted an analytical review of 194 full papers on interferon (IFN) therapy for chronic hepatitis C to evaluate current methodology (i.e. study design, criteria for evaluating the efficacy of therapy and predictors of response). Of the papers evaluated, 64 were randomized controlled trials (RCT), 40 were non-rand...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.2000.00214.x

    authors: Kondili LA,Taliani G,Tosti ME,De Bac C,Pasquazzi C,Mele A

    更新日期:2000-05-01 00:00:00

  • The molecular basis of hepatitis B e antigen (HBeAg)-negative infections.

    abstract::Hepatitis B e antigen (HBeAg)-negative infections are an unusual form of chronic hepatitis B virus (HBV) infection in which viral replication and liver damage persist despite antibodies against HBeAg. This form of HBV may be associated with fulminant hepatitis. The molecular basis for an HBeAg-minus phenotype has been...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2893.1997.00101.x

    authors: Miyakawa Y,Okamoto H,Mayumi M

    更新日期:1997-01-01 00:00:00

  • Prevalence of HBsAg/HBeAg amongst 1 936 801 couples preparing for pregnancy in rural China: An observational study.

    abstract::There are few extant studies on the prevalence of HBV infection in couples preparing for pregnancy. We assessed the prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in couples preparing for pregnancy in rural China, and the association between HBV prevalence and the statuses of HBsAg...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12693

    authors: Liu J,Zhang S,Wang Q,Shen H,Zhang M,Zhang Y,Yan D,Liu M

    更新日期:2017-08-01 00:00:00

  • Augmentation of hepatitis C virus-specific immunity and sustained virologic response.

    abstract::Treatment for chronic hepatitis C virus (HCV) infection has rapidly evolved into interferon-free directly acting antiviral regimens (DAA) that result in high sustained virologic response. DAAs primarily work by suppressing HCV replication and rely less on the immune system than interferon-based therapies. However, it ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12702

    authors: Shrivastava S,Wilson E,Poonia B,Tang L,Osinusi A,Kohli A,Kottilil S

    更新日期:2017-09-01 00:00:00

  • TyG index, HOMA score and viral load in patients with chronic hepatitis C due to genotype 1.

    abstract::The triglycerides × glucose (TyG) index is a recently proposed surrogate marker of insulin resistance (IR), calculated from fasting plasma triglyceride and glucose concentrations. We tested the host and viral factors associated with Tyg and homeostasis model assessment (HOMA) scores, comparing their associations with ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2011.01439.x

    authors: Petta S,Di Marco V,Di Stefano R,Cabibi D,Cammà C,Marchesini G,Craxì A

    更新日期:2011-07-01 00:00:00

  • Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic options.

    abstract::A significant proportion of chronic hepatitis C patients fails to achieve sustained virologic response even after treatment with the current, more potent, combination of pegylated interferon-alpha (IFNa) plus ribavirin. Such patients represent a rather heterogeneous group and may be divided initially into relapsers an...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2004.00522.x

    authors: Papatheodoridis GV,Cholongitas E

    更新日期:2004-07-01 00:00:00

  • Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-α and ribavirin therapy.

    abstract::There is little data on the long-term follow-up outcomes of chronic hepatitis C patients achieving sustained virological response (SVR) after treatment with peglylated interferon-α plus ribavirin. We prospectively investigated the overall clinical, biochemical, virological and histological outcomes in a ten-year cohor...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12574

    authors: Wang X,Gao F,Yuan G,Shi K,Huang Y,Chen Y,Qiu R,Sun L,Liu J,Hu C,Zhou Y

    更新日期:2016-12-01 00:00:00

  • Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.

    abstract::We evaluated the shift in the characteristics of people who received interferon-based hepatitis C virus (HCV) treatments and those who received recently introduced direct-acting antivirals (DAAs) in British Columbia (BC), Canada. The BC Hepatitis Testers Cohort includes 1.5 million individuals tested for HCV or HIV, o...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12684

    authors: Janjua NZ,Islam N,Wong J,Yoshida EM,Ramji A,Samji H,Butt ZA,Chong M,Cook D,Alvarez M,Darvishian M,Tyndall M,Krajden M

    更新日期:2017-08-01 00:00:00

  • Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus.

    abstract::Hepatitis C virus (HCV) is a human hepatotropic virus, but many hepatoma cell lines are not permissive to this virus. In a previous study, we observed that SNU-182, SNU-398 and SNU-449 hepatoma cell lines were nonpermissive to HCV. To understand the nonpermissivity, we evaluated the ability of each cell line to suppor...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12767

    authors: Fournier C,Hoffmann TW,Morel V,Descamps V,Dubuisson J,Brochot E,Francois C,Duverlie G,Castelain S,Helle F

    更新日期:2018-01-01 00:00:00

  • Inpatient resource utilization, disease severity, mortality and insurance coverage for patients hospitalized for hepatitis C virus in the United States.

    abstract::Although the incidence of new hepatitis C virus (HCV) infection has fallen, HCV-related complications are on the rise. Our aim was to assess and describe the 2005-2009 national inpatient mortality and resource utilization trends for patients with HCV. Data from the National Inpatient Sample (NIS) and the National Hosp...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12262

    authors: Younossi ZM,Otgonsuren M,Henry L,Arsalla Z,Stepnaova M,Mishra A,Venkatesan C,Hunt S

    更新日期:2015-02-01 00:00:00

  • Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?

    abstract::Despite the recent progress in antiviral therapy of chronic hepatitis B, clinical experience has shown that antiviral drug resistance is inevitable with the administration of nucleoside analog monotherapy. The long-term persistence of the viral genome in infected cells and the high rate of spontaneous mutation is the ...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2893.2007.00915.x

    authors: Zoulim F,Buti M,Lok AS

    更新日期:2007-11-01 00:00:00

  • Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

    abstract::We compared sustained virological response (SVR) in chronic hepatitis C patients with severe fibrosis treated with pegylated interferon (Peg-IFN) alpha-2b 1.5 microg/kg/week or 0.75 microg/kg/week in combination with ribavirin 800 mg/day for 48 weeks. This was a multicentre randomized controlled study. SVR was observe...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2893.2006.00768.x

    authors: Abergel A,Hezode C,Leroy V,Barange K,Bronowicki JP,Tran A,Alric L,Castera L,Bernard PH,Henquell C,Lafeuille H,Ughetto S,Darcha C,Chevallier M,Martineau N,Dubost S,Randl K,Dhumeaux D,Bommelaer G,Bonny C,French mult

    更新日期:2006-12-01 00:00:00

  • Evolution of glomerular filtration rate in HIV-infected, HIV-HBV-coinfected and HBV-infected patients receiving tenofovir disoproxil fumarate.

    abstract::We aimed to compare the evolution of estimated glomerular filtration rate (eGFR) in HIV-, HIV-HBV- and HBV-infected patients treated with tenofovir disoproxil fumarate (TDF). Three groups of patients receiving TDF > 12 months were recruited: 194 HIV-infected patients, 85 HIV-HBV-coinfected patients and 50 HBV-infected...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12088

    authors: Pradat P,Le Pogam MA,Okon JB,Trolliet P,Miailhes P,Brochier C,Maynard M,Bailly F,Zoulim F,Cotte L

    更新日期:2013-09-01 00:00:00

  • The efficacy and safety of treating hepatitis C in patients with a diagnosis of schizophrenia.

    abstract::Treating chronic hepatitis C with pegylated interferon alpha may induce or exacerbate psychiatric illness including depression, mania and aggressive behaviour. There is limited data regarding treatment in the context of chronic schizophrenia. We sought to establish the safety and efficacy of treating patients with sch...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12234

    authors: Mustafa MZ,Schofield J,Mills PR,Priest M,Fox R,Datta S,Morris J,Forrest EH,Gillespie R,Stanley AJ,Barclay ST

    更新日期:2014-07-01 00:00:00

  • Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.

    abstract::Socio-demographic and behavioural characteristics are associated with delayed diagnosis and disease progression in HCV-infected persons. However, many analyses focused on single variables rather than groups defined by several variables. We used latent class analysis to study all 4488 persons enrolled in the Swiss Hepa...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12535

    authors: Giudici F,Bertisch B,Negro F,Stirnimann G,Müllhaupt B,Moradpour D,Cerny A,Keiser O,Swiss Hepatitis C Cohort Study.

    更新日期:2016-09-01 00:00:00

  • Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.

    abstract::Pegylated interferon-α (PEG-IFN-α) plus ribavirin (RBV) treatment fails to achieve a sustained virological response (SVR) in approximately 20-50% of patients with chronic hepatitis C virus (HCV) infection. We assessed the contribution of an anti-IFN-α neutralizing antibody (NAb) on the nonresponse to treatment. NAbs w...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/j.1365-2893.2012.01598.x

    authors: Matsuda F,Torii Y,Enomoto H,Kuga C,Aizawa N,Iwata Y,Saito M,Imanishi H,Shimomura S,Nakamura H,Tanaka H,Iijima H,Tsutsui H,Tanaka Y,Nishiguchi S

    更新日期:2012-10-01 00:00:00

  • Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C.

    abstract:BACKGROUND AND AIMS:New therapies for HCV are rapidly emerging and providers are advising select patients to defer treatment and elect 'watchful waiting'. During the watchful waiting period, patients have been shown to have high rates of illness uncertainty and depression. We sought to answer the question of whether re...

    journal_title:Journal of viral hepatitis

    pub_type: 杂志文章

    doi:10.1111/jvh.12207

    authors: Colagreco JP,Bailey DE,Fitzpatrick JJ,Musil CM,Afdhal NH,Lai M

    更新日期:2014-10-01 00:00:00